Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AACR: AstraZeneca PARP inhibitor gives 'bang for your buck'
First-in-human results for AstraZeneca's saruparib showed an objective response rate of 48.8% in 31 patients.
Annalee Armstrong
Apr 9, 2024 5:00am
AACR: Dogs, smoothies and AstraZeneca's nap-worthy carpet
Apr 8, 2024 5:00am
AstraZeneca melds with Fusion in $2B radiopharma buyout
Mar 19, 2024 5:52am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am
AstraZeneca inks $800M buyout to snag phase 3 rare disease drug
Mar 14, 2024 9:47am
SCRI and AstraZeneca to collab on cancer clinical trials
Feb 29, 2024 7:05am